Compare Cardinal Health Inc (CAH) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs MasTec Inc — how do they compare? Cardinal Health Inc trades at $228.82 (market cap $53.89B), while MasTec Inc trades at $365.47 (market cap $28.85B). The key difference: Cardinal Health Inc is the larger of the two by market cap, and Cardinal Health Inc pays a 0.89% dividend while MasTec Inc pays none. Which is the better fit depends on your goals.
| CAH | MTZ | |
|---|---|---|
Market Cap | $53.89B | $28.85B |
Sector | Health | Technology |
52-Week High | $239.71 | $437.51 |
52-Week Low | $146.04 | $171.92 |
Enterprise Value | $58.87B | $31.60B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
MasTec (MTZ) trades at $360.21, down 3.4% on the day, with a bearish technical signal despite strong fundamental performance. The company recently announced a $1.65 billion acquisition of The Superior Group to expand its data center infrastructure capabilities, boosting its position in AI-driven markets. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 showing 34% revenue growth and 73% adjusted EBITDA growth, supported by a record $20.3 billion backlog.
Wall Street maintains strong bullish sentiment with 89% buy ratings and a $481.77 consensus price target suggesting 34% upside potential. Key risks include integration challenges from the large acquisition and premium valuation metrics. The stock's current weakness presents a potential buying opportunity for investors bullish on infrastructure spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
